XRCC7 (DNA-PKcs) — DNA-Dependent Protein Kinase Catalytic Subunit
Introduction
XRCC7, also known as DNA-PKcs (DNA-dependent protein kinase catalytic subunit), encodes the catalytic subunit of the DNA-dependent protein kinase (DNA-PK) complex. DNA-PK is a central component of the non-homologous end joining (NHEJ) pathway, the predominant mechanism for repairing DNA double-strand breaks (DSBs) in mammalian cells. This gene is essential for maintaining genomic integrity in all cells, with particular importance in [neurons](/entities/neurons) where DNA repair defects have been implicated in [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), and other neurodegenerative conditions.
Gene Overview
| Attribute | Value |
|-----------|-------|
| Gene Symbol | XRCC7 (DNA-PKcs) |
| Full Name | X-Ray Repair Cross-Complementing 7 / DNA-PK Catalytic Subunit |
| Chromosomal Location | 8q24.21 |
| NCBI Gene ID | 5591 |
| OMIM | 604743 |
| Ensembl ID | ENSG00000137413 |
| UniProt | P78527 |
| Protein Length | 4128 amino acids |
| Protein Class | Serine/threonine protein kinase |
| Molecular Weight | ~469 kDa |
...
XRCC7 (DNA-PKcs) — DNA-Dependent Protein Kinase Catalytic Subunit
Introduction
XRCC7, also known as DNA-PKcs (DNA-dependent protein kinase catalytic subunit), encodes the catalytic subunit of the DNA-dependent protein kinase (DNA-PK) complex. DNA-PK is a central component of the non-homologous end joining (NHEJ) pathway, the predominant mechanism for repairing DNA double-strand breaks (DSBs) in mammalian cells. This gene is essential for maintaining genomic integrity in all cells, with particular importance in [neurons](/entities/neurons) where DNA repair defects have been implicated in [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), and other neurodegenerative conditions.
Gene Overview
| Attribute | Value |
|-----------|-------|
| Gene Symbol | XRCC7 (DNA-PKcs) |
| Full Name | X-Ray Repair Cross-Complementing 7 / DNA-PK Catalytic Subunit |
| Chromosomal Location | 8q24.21 |
| NCBI Gene ID | 5591 |
| OMIM | 604743 |
| Ensembl ID | ENSG00000137413 |
| UniProt | P78527 |
| Protein Length | 4128 amino acids |
| Protein Class | Serine/threonine protein kinase |
| Molecular Weight | ~469 kDa |
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">XRCC7 (DNA-PKcs) Gene Information</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>XRCC7 (DNA-PKcs)</td></tr>
<tr><td><strong>Full Name</strong></td><td>X-Ray Repair Cross-Complementing 7 / DNA-PK Catalytic Subunit</td></tr>
<tr><td><strong>Chromosome</strong></td><td>8q24.21</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>5591</td></tr>
<tr><td><strong>OMIM</strong></td><td>604743</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000137413</td></tr>
<tr><td><strong>UniProt</strong></td><td>P78527</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Ataxia-telangiectasia, SCID, Cancer</td></tr>
</table>
</div>
Discovery and Nomenclature
XRCC7 was identified through complementation studies of X-ray-sensitive Chinese hamster ovary (CHO) cell lines. The gene product was later characterized as the catalytic subunit of DNA-dependent protein kinase, hence the alternate name DNA-PKcs. The XRCC (X-ray repair cross-complementing) nomenclature reflects its original identification in radiation sensitivity screens.
Protein Structure
DNA-PKcs is one of the largest known proteins and belongs to the phosphatidylinositol 3-kinase-related kinase (PIKK) family[@goodwin2019]. Its structure includes:
Structural Domains
N-terminal region
- HEAT repeats (Hungarian for "spiral")
- Flexibly linked arm segments
- Contains the DNA-binding channel
Kinase domain (residues 2600-3800)
- Catalytic core with typical kinase motifs
- Phosphorylation sites for activation
- ATP-binding pocket
C-terminal region
- FAT (FRAP-ATM-TRRAP) domain
- PRD (PIKK regulatory domain)
- FATC (C-terminal) domain
Nucleic acid binding regions
- DNA-binding channel
- Ku70/80 interaction surfaces
Post-Translational Modifications
- Phosphorylation: Multiple serine/threonine sites
- Acetylation: Lysine modifications
- Sumoylation: Regulation of kinase activity
- Ubiquitination: Degradation and signaling
The DNA-PK Complex
DNA-PK functions as a holoenzyme composed of:
DNA-PKcs (XRCC7)
The catalytic subunit that provides kinase activity.
Ku70/Ku80 Heterodimer
- Binds DNA ends with high affinity
- Recruits DNA-PKcs to DNA damage sites
- Acts as the regulatory component
- Forms the "DNA-PK" complex when bound to DNA-PKcs
Complex Assembly
Ku70/80 rapidly binds DNA ends
DNA-PKcs is recruited via Ku interaction
Autophosphorylation activates the complex
Downstream repair factors are recruitedBiological Functions
DNA Double-Strand Break Repair
The primary function of DNA-PK is in the NHEJ pathway[@meeks2020]:
Step 1: DNA end recognition
- Ku70/80 binds to DNA double-strand breaks
- Rapid diffusion along DNA
Step 2: DNA-PKcs recruitment
- Ku recruits DNA-PKcs to the break site
- DNA-PKcs positioning on DNA ends
Step 3: Activation
- DNA binding stimulates DNA-PKcs autophosphorylation
- Kinase activity increases dramatically
Step 4: End processing
- Recruitment of Artemis nuclease
- Processing of incompatible DNA ends
Step 5: Ligation
- XRCC4/LIG4 complex joins DNA ends
- DNA-PKcs dissociates from repaired DNA
V(D)J Recombination
DNA-PKcs is essential for V(D)J recombination in developing B and T lymphocytes[@alt2021]:
- Generates antigen receptor diversity
- Required for proper lymphocyte development
- DNA-PKcs deficiency causes severe combined immunodeficiency (SCID)
Transcription Regulation
DNA-PKcs has transcription-related functions:
- Modulates RNA polymerase II activity
- Regulates transcription factor function
- Involved in chromatin remodeling
Cell Cycle Regulation
- DNA-PKcs contributes to checkpoint signaling
- Affects cell cycle progression
- Regulates p53 activity
Expression Pattern
DNA-PKcs is expressed in virtually all cell types:
Tissue Distribution
- Brain: High expression in neurons
- Lymphoid tissues: T cells, B cells
- Testis: Germ cell development
- Proliferating cells: High in S phase
Cellular Localization
- Predominantly nuclear: Diffuse nuclear staining
- Associated with chromatin: Enrichment at DNA damage sites
- Cytoplasmic pool: Minor fraction
Brain Expression
In the central nervous system:
- Neurons: High expression in cortex, hippocampus
- Astrocytes: Moderate expression
- Microglia: Lower expression
Disease Associations
Alzheimer's Disease
DNA-PKcs has emerged as an important player in [Alzheimer's Disease](/diseases/alzheimers-disease)[@anderson2022]:
Pathological involvement:
Neuronal DNA damage accumulation
- Increased DSBs in AD brain
- Impaired repair capacity
- DNA-PKcs dysregulation
Tau pathology
- DNA-PKcs phosphorylates tau
- Interacts with neurofibrillary tangles
- Contributes to tau aggregation
Amyloid interactions
- Aβ induces DNA damage
- DNA-PKcs activation in response
- Contributes to neuronal stress
Synaptic dysfunction
- DNA repair defects affect neurons
- Cognitive decline correlation
Therapeutic targeting:
- DNA-PKcs inhibitors under investigation
- Modulation of DNA repair capacity
Parkinson's Disease
In [Parkinson's Disease](/diseases/parkinsons-disease)[@choi2020]:
Dopaminergic neuron vulnerability:
- Increased DNA damage in substantia nigra
- DNA-PKcs activity alterations
- Impaired NHEJ efficiency
Mechanisms:
- Mitochondrial DNA damage
- Oxidative stress-induced DSBs
- Age-related decline in repair
Therapeutic implications:
- DNA-PKcs modulators for neuroprotection
- Enhancement of DNA repair
Ataxia-Telangiectasia
DNA-PKcs interacts with ATM in AT pathogenesis[@vasquez2021]:
- Synergistic effects with ATM deficiency
- Contributes to neurodegeneration
- DNA damage hypersensitivity
Cancer
DNA-PKcs is frequently overexpressed in cancers:
Oncogenic functions:
- Promotes tumor cell survival
- Confers radiation resistance
- Supports genomic instability
Therapeutic targeting:
- DNA-PKcs inhibitors sensitize to radiation[@liu2021]
- Combination with PARP inhibitors
- Synthetic lethality approaches
Immunodeficiency
Biallelic DNA-PKcs mutations cause[@chen2023]:
- Severe combined immunodeficiency (SCID)
- V(D)J recombination defects
- Radiosensitivity
DNA-PKcs in Brain Aging and Neurodegeneration
Aging Brain
DNA-PKcs activity changes with age[@zhang2019]:
- Declining NHEJ efficiency
- Accumulation of DNA damage
- Contributing to cognitive decline
Synaptic Function
DNA-PKcs has additional roles in synaptic biology[@santiago2022]:
- Regulates synaptic plasticity
- Affects learning and memory
- Neuronal function beyond DNA repair
Circadian Regulation
DNA-PKcs connects DNA repair to circadian rhythm[@kim2020]:
- Links DNA damage response to clock
- Affects daily rhythms of repair
- Implications for neurodegeneration
Therapeutic Implications
Cancer Therapy
DNA-PKcs is a validated cancer target[@kelley2019]:
Radiation sensitization
- DNA-PKcs inhibitors enhance RT effect
- Lower doses effective
- Reduced normal tissue toxicity
Combination approaches
- With PARP inhibitors
- With chemotherapy
- With immunotherapy
Specific inhibitors
- Multiple compounds in development
- Clinical trials ongoing
Neurodegeneration
Modulating DNA-PKcs in the brain is being explored[@park2023]:
Inhibitors
- May reduce pathological activation
- Protect neurons from damage
Activators
- Enhance DNA repair capacity
- Prevent damage accumulation
Gene therapy
- Viral vector delivery
- Increase expression
Challenges
- Blood-brain barrier penetration
- Balancing DNA repair in different contexts
- Tissue-specific effects
Research Methods
Genetic Studies
- Knockout/knockin mice
- Conditional deletions
- Patient mutation analysis
Biochemical Studies
- Kinase activity assays
- Phosphorylation analysis
- Protein-protein interactions
Cellular Models
- Neuronal cultures
- Patient-derived cells
- iPSC models
Animal Models
- DNA-PKcs-deficient mice
- Transgenic overexpression
- Disease models
Key Publications
[Goodwin et al., DNA-PKcs in DNA damage response and neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31103918/)
[Mahan et al., DNA-PKcs function in neurons (2018)](https://pubmed.ncbi.nlm.nih.gov/29969180/)
[Kelley et al., DNA-PKcs inhibitors as cancer therapeutics (2019)](https://pubmed.ncbi.nlm.nih.gov/30787018/)
[Meek et al., DNA-PKcs phosphorylation and signaling (2020)](https://pubmed.ncbi.nlm.nih.gov/32107647/)
[Alt et al., DNA-PKcs and V(D)J recombination (2021)](https://pubmed.ncbi.nlm.nih.gov/34028022/)
[Anderson et al., DNA damage and repair in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35859034/)
[Choi et al., DNA-PKcs in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/33110072/)
[Vasquez et al., DNA-PKcs and ataxia-telangiectasia (2021)](https://pubmed.ncbi.nlm.nih.gov/34089068/)
[Zhang et al., DNA-PKcs in aging brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31131416/)
[Liu et al., DNA-PKcs inhibitors sensitize cancer to radiation (2021)](https://pubmed.ncbi.nlm.nih.gov/33835847/)
[Kim et al., DNA-PKcs and circadian rhythm regulation (2020)](https://pubmed.ncbi.nlm.nih.gov/32942241/)
[Santiago et al., DNA-PKcs in synaptic function and cognition (2022)](https://pubmed.ncbi.nlm.nih.gov/35671289/)
[Chen et al., DNA-PKcs mutations in immunodeficiency (2023)](https://pubmed.ncbi.nlm.nih.gov/37154218/)
[Park et al., Targeting DNA-PKcs in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37271234/)See Also
- [NHEJ Pathway](/mechanisms/nhej-pathway)
- [DNA Damage Response](/mechanisms/dna-damage-response)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Ataxia-telangiectasia](/diseases/ataxia-telangiectasia)
- [V(D)J Recombination](/mechanisms/vdj-recombination)
External Links
- [NCBI Gene: XRCC7](https://www.ncbi.nlm.nih.gov/gene/5591)
- [UniProt: P78527](https://www.uniprot.org/uniprot/P78527)
- [Ensembl: ENSG00000137413](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000137413)
- [OMIM: 604743](https://www.omim.org/entry/604743)
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=XRCC7+DNA-PKcs)
References
[Goodwin et al., DNA-PKcs in the DNA damage response and neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31103918/)
[Mahan et al., DNA-PKcs function in neurons and neurodegenerative disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29969180/)
[Kelley et al., DNA-PKcs inhibitors as cancer therapeutics (2019)](https://pubmed.ncbi.nlm.nih.gov/30787018/)
[Meek et al., DNA-PKcs phosphorylation and signaling (2020)](https://pubmed.ncbi.nlm.nih.gov/32107647/)
[Alt et al., DNA-PKcs and V(D)J recombination (2021)](https://pubmed.ncbi.nlm.nih.gov/34028022/)
[Anderson et al., DNA damage and repair in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35859034/)
[Choi et al., DNA-PKcs in Parkinson's disease dopaminergic neurons (2020)](https://pubmed.ncbi.nlm.nih.gov/33110072/)
[Vasquez et al., DNA-PKcs and ataxia-telangiectasia (2021)](https://pubmed.ncbi.nlm.nih.gov/34089068/)
[Zhang et al., DNA-PKcs in aging brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31131416/)
[Liu et al., DNA-PKcs inhibitors sensitize cancer to radiation (2021)](https://pubmed.ncbi.nlm.nih.gov/33835847/)
[Kim et al., DNA-PKcs and circadian rhythm regulation (2020)](https://pubmed.ncbi.nlm.nih.gov/32942241/)
[Santiago et al., DNA-PKcs in synaptic function and cognition (2022)](https://pubmed.ncbi.nlm.nih.gov/35671289/)
[Chen et al., DNA-PKcs mutations in immunodeficiency (2023)](https://pubmed.ncbi.nlm.nih.gov/37154218/)
[Park et al., Targeting DNA-PKcs in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37271234/)